Osteomyelitis: an overview of antimicrobial therapy by Gomes, Diana et al.
*Correspondence: A. F. Bettencourt. Faculdade de Farmácia, Universi-
dade de Lisboa. Av. Prof. Gama Pinto, 1600-083 - Lisboa, Portugal. E-mail: 
asimao@ff.ul.pt
R
ev
ie
w
Brazilian Journal of 
Pharmaceutical Sciences
vol. 49, n. 1, jan./mar., 2013
Osteomyelitis: an overview of antimicrobial therapy
Diana Gomes1, Margarida Pereira2, Ana Francisca Bettencourt1,*
1Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon, Lisbon, 
Portugal, 2Santa Cruz Hospital, Lisbon, Carnaxide, Portugal
Osteomyelitis is an inflammatory bone disorder caused by infection, leading to necrosis and destruction 
of bone. It can affect all ages, involve any bone, become a chronic disease and cause persistent morbidity. 
Treatment of osteomyelitis is challenging particularly when complex multiresistant bacterial biofilm has 
already been established. Bacteria in biofilm persist in a low metabolic phase, causing persistent infection 
due to increased resistance to antibiotics. Staphylococcus aureus and Staphylococcus epidermidis are the 
most common causative organism responsible for more than 50% of osteomyelitis cases. Osteomyelitis 
treatment implies the administration of high doses of antibiotics (AB) by means of endovenous and oral 
routes and should take a period of at least 6 weeks. Local drug delivery systems, using non-biodegradable 
(polymethylmethacrylate) or biodegradable and osteoactive materials such as calcium orthophosphates 
bone cements, have been shown to be promising alternatives for the treatment of osteomyelitis. These 
systems allow the local delivery of AB in situ with bactericidal concentrations for long periods of time 
and without the toxicity associated with other means of administration. This review examines the most 
recent literature evidence on the causes, pathogeneses and pharmacological treatment of osteomyelitis. 
The study methodology consisted of a literature review in Google Scholar, Science Direct, Pubmed, 
Springer link, B-on. Papers from 1979 till present were reviewed and evaluated.
Uniterms: Osteomyelitis/pharmacological treatment. Osteomyelitis/antimicrobial therapy. Staphylococcus 
aureus/presence/Osteomyelitis. Antibiotics/use/osteomyelitis treatment.
A osteomielite é um processo inflamatório do tecido ósseo, de origem infecciosa, que resulta em destruição 
inflamatória, necrose e formação de novo osso. Pode aparecer em qualquer idade, afetar qualquer osso 
e tornar-se uma doença crônica com morbidade persistente. Apesar dos progressos na quimioterapia 
infecciosa, o tratamento da osteomielite é caro e difícil, em particular quando associada à presença 
de biofilmes bacterianos, especialmente de Staphylococcus aureus e Staphylococcus epidermidis. 
O tratamento da osteomielite inclui a administração de doses elevadas de antibióticos (AB) por via 
endovenosa e oral, durante um período de pelo menos 6 semanas. Os sistemas de veiculação localizada de 
fármacos, utilizando materiais não biodegradáveis (polimetilmetacrilato) ou biodegradáveis e osteoativos 
como os cimentos ósseos de ortofosfatos de cálcio e vidro bioativo, surgiram como uma alternativa 
promissora para o tratamento da osteomielite. Estes sistemas permitem a veiculação de AB in situ com 
concentrações bactericidas por longos períodos de tempo e sem a toxicidade associada às outras vias de 
administração. O presente trabalho propõe uma revisão da literatura relativa às causas, à patogenia e ao 
tratamento farmacológico da osteomielite. A metodologia do estudo da revisão consistiu numa pesquisa 
bibliográfica, nas bases de dados Google Scholar, Science Direct, Pubmed, Springer link, B-on. Foram 
revistos e analisados diversos artigos publicados desde o ano de 1979.
Unitermos: Osteomielite/tratamento farmacológico. Osteomielite/terapia antimicrobial. Staphylococcus 
aureus/presença/osteomielite. Antibióticos/uso/tratamento da osteomielite.
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INTRODUCTION
Osteomyelitis known since antiquity was first 
described by Chassaignac in 1852 (Lew, Waldvogel, 
1997; Lindfors et al., 2010). The word “osteomyelitis” 
is derived from the ancient Greek words osteon (meaning 
bone) and muelinos (meaning marrow) and simply means 
an infection of the medullar portion of the bone. Common 
medical literature extends its definition to an inflam-
matory process of the entire bone including the cortex 
and the periosteum, accompanied by bone destruction 
and caused by an infecting organism (Lew, Waldvogel, 
2004).
Osteomyelitis is a disease in transition, with 
ongoing changes in predisposing factors, causative 
organisms and treatment (Tice et al., 2003a). It affects 
both adults and children. Patients with certain condi-
tions such as intravenous drug users, decubitus ulcers, 
surgery, trauma, immunosuppression, immune diseases 
(i.e. rheumatoid arthritis), diabetes mellitus, smoking, 
malnutrition, malignancy, extremes of age, chronic hy-
poxia, and renal or hepatic failure are at increased risk 
of osteomyelitis (Chihara, Segreti, 2010; Eid, Berbari, 
2012).
Prognosis of osteomyelitis is largely dependent on 
the mechanism of infection, the virulence of the infecting 
organism and the immune status and comorbid conditions 
of the patient (Tice et al., 2003b; Chihara, Segreti, 2010). 
The mortality rate is low, unless associated with sepsis or 
when a serious underlying medical condition is present. 
However, morbidity can be significant, and may include 
localized dissemination to soft tissues and joints associated 
with it (Lew, Waldvogel, 2004; Chihara, Segreti, 2010; 
McNally, Nagarajah, 2010).
Osteomyelitis is a disease which is heterogeneous 
in its pathophysiology, clinical presentation and manage-
ment. It is felt to be one of the most difficult-to-treat infec-
tious diseases (Sia, Berbari, 2006).
It continues to be a frequent indication for the use of 
intravenous antibiotic therapy as well as a major healthcare 
cost item (Tice et al., 2003a). Carrier systems that deliver 
antibiotics locally are widely-used experimentally and 
clinically to treat osteomyelitis because they can provide 
higher concentrations of drugs at the infected site (Zhang 
et al., 2010).
Osteomyelitis remains a severe problem worldwide, 
causing plenty of hospital admissions and entailing consid-
erable expense (Frank et al., 2011). This review focuses on 
current knowledge of the disease and the progress being 
made in antimicrobial treatment including the use of local 
drug delivery systems.
TERMINOLOGY
Acute osteomyelitis is an infection characterized by 
edema, locally decreased blood supply and pus formation. 
The term is often used interchangeably with hematogenous 
osteomyelitis and refers to osteomyelitis before osteo-
necrosis has occurred (Lew, Waldvogel, 2004; Chihara, 
Segreti, 2010). Acute osteomyelitis can develop after 
bacteremia, mostly in prepubertal children and in elderly 
patients (Lew, Waldwogel, 2011).
Untreated or due to treatment failure, the infection 
can progress to a more chronic phase. Chronic osteomy-
elitis is defined as bone infection in the presence of osteo-
necrosis. It is associated with formation of a large area of 
devascularized dead bone, a sequestrum (Lew, Waldvogel, 
2004; Chihara, Segreti, 2010; Lindfors et al., 2010).
PATHOGENIC MECHANISM OF INFECTION
Experimental animal models of bone infection have 
revealed that bone is highly resistant to infection. Thus, 
osteomyelitis arises only when there is a large organism 
inoculation, trauma leading to bone damage, or the pres-
ence of foreign material (Eid, Berbari, 2012).
The pathophysiology of osteomyelitis is multifacto-
rial and begins with spread of the organism. Bacteria may 
reach the bone by hematogenous seeding, direct inocula-
tion, or airborne contamination (Gogia et al., 2009). Fun-
gal osteomyelitis is more likely to result from disseminated 
fungal infection than direct inoculation of the bone (Eid, 
Berbari, 2012).
Based upon the pathogenic mechanisms of infection, 
various types of osteomyelitis can be grouped according 
to the source of the infection (Lew, Waldvogel, 2004):
1)  Osteomyelitis secondary to a contiguous focus of 
infection (e.g, after trauma, surgery, or insertion of 
a prosthetic joint);
2)  Osteomyelitis secondary to a contiguous focus of 
infection associated with vascular insufficiency, 
primarily occurring in patients with diabetes mellitus 
and/or peripheral vascular disease (Hartemann-
-Heurtier, Senneville, 2008; Lavery et al., 2009);
3)  Osteomyelitis following hematogenous spread of 
infection, which is the major mechanism in verte-
bral osteomyelitis and in children (Macnicol, Watts, 
2005; Labbé et al., 2010; Zimmerli, 2010; Pääkkö-
nen, Peltola, 2011).
Whatever the source of infection, once an organism 
reaches the bone it causes acute inflammation. Bacteria have 
various different mechanisms to facilitate cell-cell and cell-
implant adhesion (Gogia et al., 2009; Montanaro et al., 2011).
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Certain major causes of infection, such as Staphy-
lococcus aureus, adhere to bone by expressing receptors 
(adhesins) for components of bone matrix (fibronectin, 
laminin, collagen, and bone sialoglycoprotein); the ex-
pression of the collagen-binding adhesion permits the 
attachment of the pathogen to cartilage (Lew, Waldvogel, 
1997; Brady et al., 2006; Chihara, Segreti, 2010; Wright, 
Nair, 2010).
During acute infection, phagocytes attempt to con-
tain invading microorganisms and, in the process, generate 
toxic oxygen radicals and release proteolytic enzymes that 
may lyse the surrounding tissues (Lew, Waldvogel, 1997).
Pus resulting from inflammatory response spreads 
into vascular channels, raising the intraosseous pressure 
and impairing blood flow. With the progression to a chronic 
state, the ischemic necrosis of bone results in the separation 
of devascularized fragments, which are called sequestrum 
(Lew, Waldvogel, 1997; Mcphee, Papadakis, 2007).
Microorganisms avoid the host defenses and anti-
biotics through a multiplicity of mechanisms including 
surviving in a dormant state inside osteoblasts, developing 
a biofilm, and acquiring a very slow metabolic rate (Brady 
et al., 2006; Montanaro et al., 2011; Eid, Berbari, 2012; 
Gould et al., 2012).
A schematic representation of the pathogenesis of 
osteomyelitis is shown in Figure 1.
CAUSAL ORGANISMS
The most common pathogens responsible for osteo-
myelitis in humans are Staphylococcus species, followed 
by Enterobacteriaceae and Pseudomonas species (Gogia 
et al., 2009). A summary of different etiology related to 
age and the predisposing conditions is shown in Table I.
Staphylococcus aureus is the most commonly iso-
lated pathogen for both acute and chronic osteomyelitis 
FIGURE 1 - Pathogenesis of osteomyelitis. I - A large inoculum of bacteria reaches the medular channel; II - (Acute state) Pus 
resulting from inflammatory response spreads into vascular channels; III - (Chronic state) Vascular channels are compressed and 
obliterated by the inflammatory process, and the resulting ischaemia also contributes to bone necrosis.
TABLE I - Most common isolated microorganisms in osteomyelitis are related to age and susceptibility factors (adapted from 
Lew, Waldvogel, 2004; Brook, 2008; McNally, Nagarajah, 2010; Chihara, Segreti, 2010; Jorge et al., 2010; Zimmerli, 2010; Eid, 
Berbari 2012)
Age Etiology
Newborn babies S. aureus, Enterobacter spp., Streptococcus (group A and B)
Children S. aureus, Enterobacter spp., Streptococcus (group B), Haemophilus influenzae
Adults S. aureus
Susceptibility factors Etiology
Injectable drug users S. aureus, P. aeruginosa, Serratia marcescens, Candida spp.
Imunocompromised S. aureus, Bartonella henselae, Aspergillus spp., Mycobacterium avium complex, Candida 
albicans
Urinary infection P. aeruginosa, Enterococcus spp. 
Spinal column surgery S. aureus, coagulase-negative staphylococci, aerobic gram-negative bacilli
Orthopedic fixation devices S. aureus, coagulase-negative staphylococci, Propionibacterium spp.
Hospitalization (nosocomial source) Enterobacteriaceae, P. aeruginosa, Candida spp.
Diabetes mellitus, vascular 
insufficiency, contaminated open 
fracture
Polimicrobial: S. aureus, Staphylococci coagulase negative, Streptococcus spp., 
Enterococcus spp., Gram-negative bacilli, anaerobes
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in all age groups (Jorge et al., 2010; Eid, Berbari, 2012). 
There has been an increase in methicillin-resistant S. 
aureus (MRSA) in recent years (Chihara, Segreti, 2010), 
due to rapid development of antimicrobial resistance and 
expression of virulence factors, regardless of the patient´s 
immune status. Coagulase-negative staphylococci are 
often seen in association with foreign bodies, such as 
prosthetic joints (Chihara, Segreti, 2010).
Haemolytic streptococci are also responsible for 
bone infection (Darley, MacGowan, 2004).
Anaerobic bacteria as Bacteroides spp., anaerobic 
cocci, Fusobacterium spp., Propionibacterium acnes 
and Clostridium spp. have received increasing recogni-
tion in the bacteriology of osteomyelitis, although the 
exact prevalence of anaerobes in this disease is unknown 
(Brook, 2008; Jorge et al., 2010; Furustrand et al., 2012). 
Anaerobes may contribute to polymicrobial osteomyelitis 
in vasculopathic infection such as diabetic foot infection 
(Eid, Berbari, 2012).
Also, Gram-negative bacteria, such as Pseudo-
monas aeruginosa and Enterobacteriaceae have grown 
in importance as causative agents due to the increasing 
number of orthopedic surgeries with the use of implants 
and, especially, the rising number of high-energy traumas 
associated with open fractures, as a consequence of traf-
fic accidents and war injuries (Chihara, Segreti, 2010; 
Carvalho et al., 2012).
Virtually any organism has the potential to cause 
osteomyelitis. For example in immunocompromised pa-
tients, pathogens such as Bartonella henselae, Aspergillus 
spp., Mycobacterium avium complex or Candida albicans 
may be isolated (Arias et al., 2004; Chihara, Segreti, 2010; 
Eid, Berbari, 2012).
ANTIMICROBIAL THERAPY FOR OSTE-
OMYELITIS
General considerations
Several medical specialties are involved in the treat-
ment of patients with osteomyelitis, including orthopaedic 
surgeons, microbiologists, and scientists in the fields of 
biology and biomechanics (Efstathopoulos et al., 2008). 
The primary goal of treatment is remission of the disease, 
which is defined as the absence of any sign of infection, 
in the initial or contiguous location, at least one year after 
the end of antimicrobial therapy (Chihara, Segreti, 2010).
The difference in pathophysiology of various types 
of osteomyelitis mandates specific therapeutic strategies 
aimed at the eradication of the infection while preserving 
bone integrity and function (Eid, Berbari, 2012; Moenster 
et al., 2012). Early antibiotic treatment, before extensive 
destruction of bone or necrosis, produces the best results 
and must be administered by the intravenous route for at 
least four (and usually six) weeks to achieve an acceptable 
rate of cure (Lew, Waldvogel, 1997). The initial choice of 
antibiotic inevitably depends on the causal pathogen and 
its susceptibility pattern. Antibiotics considered bacteri-
cidal against the infecting organisms are often considered 
necessary (Darley, MacGowan, 2004).
Acute osteomyelitis is usually successfully treated 
with intravenous antibiotics (Lew, Waldvogel, 2004; Dar-
ley, MacGowan, 2004).
The treatment of chronic osteomyelitis is more 
complicated and requires a multidisciplinary approach 
in 3 phases: surgical debridement, systemic antibiotic 
therapy for 4 to 6 weeks and local antibiotic delivery 
systems (Sánchez et al., 2001; Aslam, Darouiche, 2009; 
Mouzopoulos, 2011). The goal of surgical treatment is to 
convert an infection with dead bone to a situation with 
well-vascularized tissues that are readily penetrated by 
antibiotics, making prolonged drug treatment unnecessary 
(Mader et al., 1993). 
Osteomyelitis surgical treatment is beyond the scope 
of the present review. Some recent data on the subject can 
be found (Lew, Waldvogel, 2004; Chihara, Segreti, 2010; 
Haidar et al., 2010; Malizos et al., 2010).
Next, we will discuss the classes of antibiotics used 
in oral and systemic antibiotic treatment and the use of lo-
cal antibiotic delivery systems mainly in the management 
of chronic osteomyelitis.
Oral and parenteral antibiotic treatment
Parenteral antimicrobial therapy remains the main-
stay of antimicrobial therapy for osteomyelitis and is 
commonly used for 4-6 weeks. An early switch to oral 
administration is appropriate for antibiotics with good 
bioavailability and bone penetration (Lew, Waldvogel, 
2004; Eid, Berbari, 2012). Combined parenteral and oral 
regimens are usually used (Calhoun, Manring, 2005). The 
advantages and disadvantages of oral and parenteral routes 
are summarized in Table II.
Beta-lactams and lincosamides
Intravenous beta-lactams antibiotics (i.e. penicil-
lins and cephalosporins) were commonly used to treat 
osteomyelitis due to their efficacy and relative safety 
when given for a prolonged period of time (Eid, Berbari, 
2012). As new oral regimens become available, and the 
prevalence of MRSA increases, intravenous beta-lactams 
are likely to become less widely used for osteomyelitis 
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TABLE II - Advantages and disadvantages of parenteral, oral and local antibiotic therapy (adapted from Gitelis, Brebach, 2002; 
Ambrose et al., 2003; Lazzarini et al., 2005)
Therapy 
Type Advantages Disadvantages
Parenteral - Delivery of antibiotic to areas that cannot be reached 
with oral therapy
- Choice of a large set of agents 
- Arrest or eradication of infection in most cases (in 
conjunction with surgical debridement)
- Often requires hospitalization
- Lack of patient compliance
- Systemic drug toxicity
- Even with prolonged intravenous antibiotic therapy 
relapse of bone infection is not uncommon
- Expensive
Oral - Ease of administration
- Reduced duration of hospitalization and health care costs 
- Therapeutically unpredictable 
- Capacity for replace the prolonged courses of 
parenteral therapy is controversial
- Limited choice of agents
 Local - Avoid high serum concentrations of the antibiotic 
- Deliver antibiotic directly to the infection site
- Reduced duration of hospitalization and health care costs 
- Lack of proven efficacy in good randomized clinical 
trials
treatment (Eid, Berbari, 2012). Oral beta-lactams are 
more effective in pediatric osteomyelitis, as compared to 
adults, as is the rate of healing (Pawar, Bhandari, 2011). 
Oral cephalosporins, e.g., cephalexin, ceftriaxone are often 
used clinically. Once-daily administered drugs, such as 
ceftriaxone, are preferred, especially for outpatient therapy 
(Lazzarini et al., 2005). Also, clindamycin is a lincosamide 
antibiotic active against most gram-positive bacteria, has 
excellent oral bioavailability and high bone serum ratios 
and is currently given orally after initial intravenous treat-
ment for 1 to 2 weeks (Calhoun, Manring, 2005; Pawar, 
Bhandari, 2011).
Fluoroquinolones
The fluoroquinolones have gained popularity in 
recent years because of their excellent oral bioavailability 
and bone penetration (Lew, Waldvogel, 2004).
Promising results have been demonstrated in several 
trials especially against Gram-positive, Gram-negative, 
and polymicrobial infections (Pawar, Bhandari, 2011). 
Extensive in vitro studies have demonstrated the role of 
the second generation fluoroquinolones like ciprofloxacin, 
ofloxacin, and pefloxacin against some Gram-positive 
organisms (Pawar, Bhandari, 2011). Yet, they have poor 
activity against Streptococcus spp., Enterococcus spp., and 
anaerobic bacteria (Calhoun, Manring, 2005).
The third-generation quinolone, levofloxacin, has 
improved Streptococcus spp. activity, but with minimal 
anaerobic coverage (Calhoun, Manring, 2005). The newer 
fourth-generation fluoroquinolones, gatifloxacin, moxi-
floxacin, and gemifloxacin cover many gram-positive and 
gram-negative organisms, and certain anaerobes. Never-
theless, newer fluoroquinolones are not as active against 
P. aeruginosa as ciprofloxacin (Calhoun, Manring, 2005).
In general, quinolones efficacy against Enterobac-
teriaceae is undisputed, an advantage over conventional 
therapy for infections with P. aeruginosa, Serratia spp., 
and S. aureus has yet to be shown in controlled studies 
(Lew, Waldvogel, 2004). In addition, the widespread use of 
quinolones has led to the emergence of quinolone-resistant 
S. aureus strains (Pawar, Bhandari, 2011), therefore the use 
of a second agent in the treatment of S. aureus infection is 
advisable (Darley, MacGowan, 2004). Fluoroquinolones 
have also been reported to inhibit fracture healing, but 
the clinical significance of this observation is not known 
(Aslam, Darouiche, 2009).
Rifampicin and fusidic acid
Rifampicin, a broad-spectrum antimicrobial agent, 
achieves high intracellular levels and is one of the few 
antimicrobial agents that can penetrate biofilms and 
kill organisms in the sessile phase of growth (Aslam, 
Darouiche, 2009). Several studies have shown that oral 
treatment with rifampicin in combination with various 
antibiotics as ciprofloxacin, ofloxacin, or fusidic acid is 
effective in bone staphylococcal infections in the presence 
of implants or prosthetic joints (Lew, Waldvogel, 2004; 
Pawar, Bhandari, 2011).
However, its utility could be limited due to the de-
velopment of resistance, inability to tolerate due to side-
effects, and frequent drug interactions.
High serum concentrations, bactericidal levels in 
infected and sclerotic bone, good intracellular concentra-
tions, and good activity against S. aureus are some of the 
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advantages of fusidic acid. Like rifampicin, early develop-
ment of resistance, is one of the prime limitations of fusidic 
acid, unless used in combination (Pawar, Bhandari, 2011). 
Rifampicin and fusidic acid are reasonable adjunctive 
agents for combination therapy (Aslam, Darouiche, 2009).
Glicopeptides 
The only drugs with a constant efficacy against all 
the staphylococcal strains, and which have been exten-
sively studied in the treatment of bone infections, are 
glycopeptides, in particular vancomycin (Yin et al., 2005; 
Courvalin, 2006). Vancomycin is used to treat MRSA and 
ampicillin-resistant Enterococcus species (Eid, Berbari, 
2012). Unfortunately, resistance to this antibiotic has al-
ready been recognized as a major problem in the treatment 
of Gram-positive pathogens and increasing data suggest 
that vancomycin is losing its clinical and microbiological 
potency. Increased prevalence of vancomycin-resistant S. 
aureus (VRSA), vancomycin-resistant enterococci (VRE) 
is already limiting its usage (Rice, 2006; Moise et al., 
2009; Pawar, Bhandari, 2011; Vilhena, Bettencourt, 2012). 
Moenster et al. (2012) states that despite adequate dosing, 
30% to 50% of patients experience infection recurrence 
within 12 months.
New agents
Newer antibiotics with high bone penetration such 
as linezolid, daptomycin and tigecycline are promising 
for treating osteomyelitis due to MRSA in patients who 
display intolerance or poor response to vancomycin but 
must be further tested in clinical trials (Lazzarini et al., 
2005; Aslam, Darouiche, 2009; Pawar, Bhandari, 2011). A 
good review on the topic was recently published by Pawar 
and Bhandari (2011).
Linezolid, which can be administered either orally 
or intravenously, represents a new class of antibiotic with 
no cross-resistance to other antibiotics. It is active against 
Gram-positive organisms including VRE (E. faecium 
and E. faecalis) and MRSA (Darley, MacGowan, 2004; 
Calhoun, Manring, 2005). It has been proved effective for 
treating serious infections, including osteomyelitis (Cal-
houn, Manring, 2005). Long-term safety and efficacy data 
needs to be produced in bone and joint infections, since 
they are lacking. Additionally, no large randomized trials 
have been published on the use of linezolid for orthopaedic 
infections (Pawar, Bhandari, 2011).
Daptomycin is a novel parenteral cyclic lipopeptide 
with bactericidal activity against multi-drug resistant 
Gram-positive organisms commonly found in osteomy-
elitis, even when the other first-line drugs have failed 
(Calhoun, Manring, 2005; Lamp et al., 2007; Pawar, Bhan-
dari, 2011; Vilhena, Bettencourt, 2012). Preliminary data 
suggests that daptomycin penetrates bone well and can be 
a potential therapeutic option for patients with MRSA or 
VRE osteomyelitis (Vilhena, Bettencourt, 2012). How-
ever, no randomized and controlled trials comparing the 
effectiveness and safety of daptomycin with other anti-
biotics used to treat bone and joint infections have been 
completed (Lamp et al., 2007; Pawar, Bhandari, 2011).
In addition, case reports suggest the potential for 
quinupristin-dalfopristin the first parenteral strepto-
gramin and tigecycline, a novel parenteral glycylcycline 
to cure chronic osteomyelitis, but clinical data are limited 
(Fraimow, 2009; Kaya et al., 2011; Pawar, Bhandari, 
2011). Long-term safety and efficacy data needs to be 
produced with regard to the use of these promising newer 
agents for treating osteomyelitis due to MRSA and van-
comycin-resistant Enterococcus (VRE).
An overview of the potential choices of antimicro-
bial agents for commonly encountered microorganisms in 
osteomyelitis and preferred routes of administration are 
listed in Table III.
Local Antibiotic Therapy
Even with prolonged intravenous antibiotics, there 
is a significant relapse rate in the treatment of chronic 
osteomyelitis. To supplement oral and systemic antibiot-
ics, local antibiotic delivery has been tried for many years 
(Gursel et al., 2001; Gitelis, Brebach, 2002; Nair et al., 
2011).
The in situ implantation of a local antibiotic delivery 
system works to obliterate bacteria in the area as well as 
to reduce the dead space in the bone (Nair et al., 2011). 
Its use results in a lower serum antibiotic concentration 
than that associated with systemic administration, thereby 
reducing toxicity-related side-effects (Joosten et al., 2005; 
Samuel et al., 2012) (Table II).
Considering the most commonly described microbes 
causing chronic osteomyelitis, the most widely acceptable 
antimicrobial agents in local delivery systems are amino 
glycosides and to a lesser extent various beta-lactam agents 
and quinolones. However, a combination therapy of anti-
biotics is useful to reduce the toxicity of individual agents, 
to prevent the emergence of resistance and to treat mixed 
infections involved in osteomyelitis (Nandi et al., 2009).
The local delivery of antibiotics in the treatment of 
osteomyelitis has been used for decades regardless of the 
controversy over its effectiveness (Gitelis, Brebach, 2002).
To retain an appropriate antibiotic level, several drug 
delivery systems have been developed in the treatment of 
chronic osteomyelitis (Gitelis, Brebach, 2002). Generally, 
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TABLE III - Antimicrobial therapy of osteomyelitis in adults for selected organisms (Chihara, Segreti, 2010; Sia, Berbari, 2010; 
Carvalho et al., 2012; Eid, Berbari, 2012)
Microorganisms First choice Alternative choice
Staphylococci
Penicillin-sensitive
Penicillin-G, 3-4 MU IV q
4 h for 4-6 wks
Ceftriaxone, 1-2 g IV q 24 hrs or 
clindamycin, 900 mg IV q 8 h
Staphylococci-methicillin-resistant 
(MRSA)
Vancomycin*, 15 mg/kg IV 
12 h for 4-6 wks (some add rifampicin*, 
600 mg PO daily)
Linezolid, 600 mg (PO/IV) q 12 h for 
6 wks (or linezolid plus rifampicin* PO 
600-900 mg/day) or daptomycin, 
6 mg/kg IV daily for 6 wks
Penicillin-sensitive
Streptococci
Penicillin-G, 20 MU IV 
24 h for 4-6 wks or
ceftriaxone, 1-2 g IV or IM
24 h for 4-6 wks
Vancomycin*, 15 mg/kg IV q 12 h for 
4-6 wks
Enterococci or streptococci with 
penicillin MIC ≥0.5 µg/mL
Penicillin-G, 3-4 MU (IV) q
4 h for 4-6 wks or
ampicillin, 2 g IV q 4 h; the addition of 
gentamicin, 1
mg/kg IV/IM q 8 h for 1-2 wks optional
Vancomycin*, 15 mg/kg IV q 12 h for 
4-6 wks; the addition of gentamicin, 
1 mg/kg IV/IM q 8 h for 1-2 wks optional
Enterobacteriaceae Ceftriaxone, 1-2 g IV q 24 h for 4-6 wks Ciprofloxacin, 500-750 mg PO q 12 h for 4-6 wks
Pseudomonas aeruginosa or 
Enterobacter spp.
Cefepime, 2 g IV q 12 h for 4-6 wks or 
meropenem, 1 g IV q 8 h for 4-6 wks
Ciprofloxacin, 750 mg PO q 12 h for 4-6 
wks, or ceftazidime, 2 g IV q 8 h
Mixed infections possibly involving 
anaerobic bacteria
Ampicillin/sulbactam, 1.5-3 g
IV q 6 h or piperacillin/tazobactam, 
3.375 g IV q 6 h
Carbapenem antibiotic or a combination of 
fluoroquinolone plus clindamycin, 900 mg 
IV t.i.d or metronidazole, 500 mg PO t.i.d
Candida species Amphotericin B 0.5-1 mg/kg daily for 2-3 wks followed by fluconazole, 6 mg/kg PO/IV daily for 6-12 mo
Legend: h-hour; IM-intramuscular; IV-intravenous; q- every; mo-months; MU-million units; PO-per os; t.i.d- three times a day; 
wks-weeks. *pharmacokinetic monitoring (allows a better efficacy and minimal adverse effects)
the delivery vehicles may be classified as nonbiodegrad-
able (or non-resorbable) and biodegradable (or resorbable) 
(Kanellakopoulou, Giamarellos-Bourboulis, 2000). In 
Table IV the main advantages and disadvantages of these 
two types of systems are outlined.
Non-Biodegradable systems
Antibiotic-impregnated polymethylmethacrylate 
(PMMA) beads and self-setting bone cement have been 
used to treat chronic osteomyelitis allowing the local de-
livery of high concentrations of antibiotics, while avoiding 
potential systemic side effects (Anagnostakos et al., 2006; 
Azi et al., 2010).
Gentamicin-impregnated beads were created by 
Klemm (1979) and were used to occupy dead space after 
debridement of infected bone related to chronic osteomy-
elitis. Klemm treated more than 100 patients in this fashion 
and a cure rate of 91.4% was achieved (Azi et al., 2010; 
Schade, Roukis, 2010).
PMMA beads containing gentamicin have been ap-
proved for use in treatment of osteomyelitis in Europe, in 
the 1970s under the trade name of Septopal®. Septopal 
beads have now been on the market for more than 30 years, 
a remarkably long time for a pharmacological product. It 
is still not accepted by the Food and Drug Administration 
(FDA) in the USA (Walenkamp, 2009).
Non-commercial preparations of beads prepared 
by surgeons themselves are also in use. Physician-made 
beads are individually manufactured by the surgeon using 
commercially available PMMA polymer mixed with a 
powdered antibiotic or can be created with the assistance 
of an individually made bead mold (Holtom, Patzakis, 
2003) (Figure 2).
However, these types of beads have the disadvantage 
of a lack of thorough mixing of the antibiotic into the mate-
rial and a lack of uniform size of bead, resulting in lower 
antibiotic availability (Kanellakopoulou, Giamarellos-
Bourboulis, 2000).
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Over the past three decades, numerous advantages 
with antibiotic-impregnated beads over systemic therapy 
have been recognized (Table IV) but their application is 
still controversial. Placement of these beads is a simple 
procedure and often performed at time of initial debride-
ment of chronic osteomyelitis (Gogia et al., 2009). Local 
antibiotic treatment is also substantially less expensive 
than systemic therapy, which can cost hundreds of dollars 
per day in an outpatient setting and much more in the hos-
pital setting. In spite of these advantages, bead placement 
generally requires a second operation for removal after the 
completion of antibiotic release. Another argument against 
its use is the lack of proof of efficacy in good randomized 
clinical trials (Walenkamp, 2009). The pros and cons re-
garding the use of gentamicin-containing PMMA beads 
were recently discussed by Barth et al. (2011).
Besides beads, the other form of antibiotic local 
delivery is by using PMMA bone cement, a powdered 
polymer mixed with a liquid monomer to form a solid 
structure.
Many antibiotics have been shown to maintain ef-
ficacy when mixed with PMMA bone cement. The most 
widely studied antibiotic is gentamicin, an excellent 
additive to PMMA due to its broad spectrum of action 
and good thermostability (Gogia et al., 2009; Azi et al., 
2010). Tobramycin and vancomycin, both water soluble 
TABLE IV - Advantages and disadvantages of different type of antibiotic carrier systems (adapted from Gursel et al., 2001; Shirtliff 
et al., 2002; Gogia et al. 2009; Walenkamp, 2009; Campoccia et al., 2010)
Carrier type Advantages Disadvantages
N
on
-b
io
de
gr
ad
ab
le
- Represent the current gold standard for local 
antibiotic delivery
- Proven to be successful with several antibiotics
- Easy procedure for insertion in the body 
- Low biocompatibility, cytotoxic effects 
- Second surgery may be needed to remove the cement 
beads (which is costly and painful) 
- Polymerization process could cause thermal damage and 
neutralize the antibiotic 
- Poor antibiotic elution properties
- Slow residual release of antibiotics for undefined periods; 
risk of resistance 
Bi
od
eg
ra
da
bl
e - Material properties can be adjusted to vary the 
release rate of the antibiotic
- Osteoconductivity and osteoinductivity
- One-stage surgery
- Wider selection of antibiotics including 
thermolabile ones 
- Do not form a firm bond with bone
- Initial burst of antibiotics to the infection site
- No large human trials have been published
- None of these materials has been approved for antibiotic 
delivery in osteomyelitis treatment by the FDA
FIGURE 2 - The in situ implantation of antibiotic-impregnated beads, as a local antibiotic delivery system, works to obliterate 
bacteria in the area as well as to reduce the dead space in the bone.
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and available in powder form, have also been included in 
PMMA (Gogia et al., 2009). But the resistance to these 
routinely used antibiotics has led to an intensive search 
for alternative, more effective antibiotics to be loaded 
into PMMA bone cement. Marra et al. (2001) described 
the treatment with amphotericin B-loaded bone cement 
of a case of osteomyelitis due to Candida albicans in 
an adult who had undergone multiple revisions of a hip 
prosthesis. Efstathopoulos et al. (2008) evaluated the 
efficacy of grepafloxacin loaded acrylic bone cement 
(polymethylmethacrylate, PMMA) for the treatment of 
experimentally chronic osteomyelitis induced in rabbits. 
Just recently, Samuel et al. (2012) evaluated the bioactivity 
of meropenem loaded bone cement with possible applica-
tion in Gram negative bone infections.
Presently, the major concern related to the use of 
PMMA-based local antibiotic delivery system refers to the 
risk of induction of antibiotic resistance due to their possible 
contribution to enhancing biofilm formation on the material 
and selecting resistant mutants (Campoccia et al., 2010).
Nevertheless, taking into account the numerous 
recently published in vitro and in vivo studies related to 
antibiotic loaded PMMA systems (Marra et al., 2001; 
Efstathopoulos et al., 2008; Samuel et al., 2012), it is 
expected they will remain in the near future an effec-
tive drug delivery system for local antibiotic therapy in 
osteomyelitis.
Biodegradable systems
In order to address some of the drawbacks of local 
delivery with PMMA, the use of local antibiotics from a 
biodegradable implant for osteomyelitis is an attractive al-
ternative and has been actively investigated in recent years. 
Major advantages of these implants include obliteration of 
dead space, aid to bone repair, wider selection of antibiot-
ics including thermolabile ones and no need for a second 
surgery for removal (Table IV) (Gitelis, Brebach, 2002).
A large number of biodegradable and biocompatible 
carrier materials such as bioceramics, polymers, bioglasses 
and composites have been tried in vitro and in vivo (Table 
V) as possible methods for local antibiotic therapy of 
osteomyelitis. Interesting reviews on the subject can 
be found in Kanellakopoulou, Giamarellos-Bourboulis 
(2000) and Nandi et al. (2009). 
Impregnation of antimicrobial agents within os-
teoconductive bioceramics (calcium sulphate, tricalcium 
phosphate or hydroxyapatite) has been proposed for the 
local management of osteomyelitis and to aid dead space 
management mainly for the delivery of aminoglicosides 
such as tobramycin (Nelson et al., 2002) and vancomycin 
(Mäkinen et al., 2005; Xie et al., 2009).
Besides bioceramics, other bioactive inorganic ma-
terials are being explored as silicate (Mäkinen et al., 2005; 
Lindfors et al., 2010) and borate-based bioglasses (Xie et 
al., 2009) for the treatment of chronic osteomyelitis.
These bone-filling materials have the advantage of 
converting to a hydroxyapatite (HA)-type material, the 
main mineral constituent of bone, and bond strongly with 
bone and soft tissue in vivo, promoting osteogenesis on 
their surfaces (Mäkinen et al., 2005; Zhang et al., 2010).
An alternative approach that has also been tested in 
the local treatment of osteomyelitis is the use of biode-
gradable polymeric carriers such as lactid acid polymers 
(Garvin et al., 1994; Kanellakopoulou, Giamarellos-Bour-
boulis, 2000; Ambrose et al., 2003, 2004) and collagen 
(Riegels-Nielsen et al., 1995) especially for antibiotics 
such as ampicillin, tobramycin and gentamicin. Recently, 
an injectable degradable polymer, poly(sebacic-co-ricin-
oleic-ester-anhydride) containing gentamicin proved to be 
efficient histologically in the treatment of osteomyelitis 
(Brin et al., 2008).
Currently, one of the most promising strategies is to 
develop organic-inorganic hybrids or composite bioma-
terials providing excellent possibilities for improving the 
conventional drug delivery systems. In this sense, several 
biocomposites composed of biodegradable polymers such 
as chitosan poly(lactic-co-glycolic acid), poly(D,L-
lactide) or poly-ε-caprolactone and inorganic materials 
like tricalcium phosphate, hydroxyapatite and bioactive 
glasses have been tried (Mäkinen et al., 2005; Alvarez et 
al., 2008; Miyai et al., 2008; Zhang et al., 2010), show-
ing promising results for curing chronic osteomyelitis in 
animal models (Table V).
To our knowledge, no large human trials have been 
published and none of these materials has been approved 
for antibiotic delivery in osteomyelitis treatment by the 
FDA.
CONCLUSIONS
Osteomyelitis is a serious deep bone infection with 
significant morbidity and high rates of recurrence. The 
infection, caused by a variety of microbial agents (the 
most common being S. aureus) can arise from a variety of 
etiologies such as trauma, nosocomial infections or after 
implant replacement surgery. Despite advances in medical 
and surgical therapies, the management of osteomyelitis 
is an increasing challenge to clinicians due to the growing 
resistance to antibiotics.
Currently, the standard treatment of osteomyelitis 
includes debridement of infected tissues, dead space 
management, and 4 to 6 weeks of parenteral antibiotics. 
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Among the numerous antibiotics that have been reported 
to be useful in the treatment of osteomyelitis, vancomy-
cin has been used for decades to treat MRSA associated 
infection. However poor vancomycin bone penetration 
and increasing rates of heteroresistance and glycopeptide 
tolerance have encouraged the search for newer agents, 
namely linezolid, daptomycin, quinupristin-dalfopristin 
and tigecycline.
Management of chronic osteomyelitis with the 
local delivery of antibiotics has the advantage of achiev-
ing high antibiotic concentrations at the site of infection 
without the systemic toxicity associated with the paren-
teral route. The most commonly used non-biodegradable 
carrier material has long been PMMA in the form of 
beads or bone cement. A novel number of biodegradable 
carriers systems have been developed in recent years with 
promising clinical potential, combining local delivery of 
the drug with osteogenic potential. This is an emerging 
area of research with great potential in the near future to 
treat osteomyelitis.
TABLE V - Example of studies exploring different biodegradable carriers materials to treat chronic osteomyelitis in animal model
Class Material Antibiotic Tested m.o. Animalmodel Reference
Bi
oc
er
am
ic
Calcium phosphate Gentamicin S. aureus Rabbits Joosten et al., 2004
Calcium sulphate Moxifloxacin MRSA Rabbits Kanellakopoulou et 
al., 2009
Calcium sulphate Tobramycin sulphate S. aureus Rabbits Nelson et al., 2002
Hydroxyapatite Vancomycin S. aureus Rabbits Shirtliff et al., 2002
Hydroxyapatite Gentamicin sulphate S. aureus Rats Korkusuz et al., 
1993
Hydroxyapatite Vancomycin MRSA Rabbits Joosten et al., 2005
Po
ly
m
er
Collagen Gentamicin S. aureus Rabbits Riegels-Nielsen et 
al., 1995
PEG, PLGA Tobramycin, 
Cefazolin
S. aureus Rabbits Ambrose et al., 2004
Polyhydroxy-alkanoate Sulbactam, 
cefoperazone, 
ampicillin
S. aureus  Rabbits Gursel et al., 2001
Polylactide/polyglicolide Gentamicin S. aureus Dogs Garvin et al., 1994
P(SA-RA) Gentamicin S. aureus Rats Brin et al., 2008
P(SA-RA) Gentamicin S. aureus Rats Krasko et al., 2007
Bi
oa
ct
iv
e 
gl
as
s
Borate Vancomycin MRSA Rabbits Xie et al., 2011
Borate Vancomycin  MRSA Rabbits Xie et al., 2009
Boro-silicate Ceftriaxone–
sulbactam
S. aureus Rabbits Kundu et al., 2011
Co
m
po
sit
e
Chitosan, borate glass Teicoplanin S. aureus Rabbits Zhang et al., 2010
PLGA, bioactive glass Ciprofloxacin S. aureus, 
S.epidermidis, E. coli, 
P. aeruginosa
Rabbits Mäkinen et al., 2005
Poly(D,L-lactide), 
tricalcium-phosphate, 
hydroxyapatite
Ciprofloxacin S. aureus Rabbits Alvarez et al., 2008
Poly-ε-caprolactone, 
tricalcium phosphate
Gatifloxacine S. milleri, B. fragilis Rabbits Miyai et al., 2008
Legend: m.o.-microorganism; MRSA-methicillin-resistant S. aureus; PEG-poly(ethylene glycol); PLGA-poly(DL-lactic-co-glycolic 
acid); P(SA-RA)-Poly(sebacic-co-ricinoleic-ester-anhydride).
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